{"id":"W3026733513","doi":"10.1016/j.jval.2020.04.1588","title":"PCN87 COST-EFFECTIVENESS OF RIBOCILIB PLUS NONSTEROIDAL AROMATASE INHIBITOR (NSAI) IN HORMONE RECEPTOR–POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–NEGATIVE (HR+/HER2-) ADVANCED BREAST CANCER (ABC): A CANADIAN HEALTHCARE PERSPECTIVE","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Discontinuation; Breast cancer; Internal medicine; Quality-adjusted life year; Population; Placebo; Oncology; Exemestane; Adverse effect; Hazard ratio; Cohort; Cancer; Cost effectiveness; Confidence interval; Pathology; Aromatase; Environmental health","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006770489,0.0006775025,0.001782431,0.0006181182,0.0002351295,0.00002051041,0.0002938485,0.000290388,0.0001625359],"category_scores_gemma":[0.0003685732,0.0007092868,0.0001879483,0.00154914,0.0004270923,0.0004774493,0.00009206677,0.001244133,0.00002168018],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01149939,"about_ca_system_score_gemma":0.004967068,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.5796829,"about_ca_topic_score_gemma":0.07378025,"domain_scores_codex":[0.9939419,0.001547941,0.001243256,0.001244921,0.0006422491,0.00137974],"domain_scores_gemma":[0.9962433,0.0005580178,0.0005976709,0.0004379397,0.0006635769,0.001499496],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1066338,0.003831738,0.3769678,0.02268918,0.001673834,0.001159219,0.2306632,0.01659177,0.1383487,0.008975331,0.001259222,0.09120618],"study_design_scores_gemma":[0.03243528,0.005325706,0.9114023,0.00942746,0.00005729212,0.0001496638,0.01913479,0.001032596,0.01777772,0.000728219,0.0008282554,0.001700681],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9421638,0.005877191,0.0001506296,0.03387477,0.0004278522,0.006889211,0.01038784,0.0001346462,0.00009402401],"genre_scores_gemma":[0.9943033,0.0006025283,0.001410388,0.002104451,0.000368868,0.0007191898,0.0003348612,0.000143299,0.00001306721],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5344346,"threshold_uncertainty_score":0.9995358,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03851986799938985,"score_gpt":0.3323232837129566,"score_spread":0.2938034157135667,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}